Abstract

A recently published phase 1 clinical trial in Nature Medicine represents the first successful demonstration of liver-targeted PCSK9 base editing for the treatment of familial hypercholesterolemia (FH). The study utilized lipid nanoparticle delivery of base editor components targeting hepatic PCSK9 expression, demonstrating proof-of-concept for in vivo gene editing as a therapeutic modality for inherited dyslipidemia. While specific efficacy data remain limited in the available publication, the trial establishes the feasibility of liver-directed base editing in patients with heterozygous FH who had inadequate response to conventional lipid-lowering therapy. The intervention demonstrated acceptable safety profiles in the limited cohort studied, with transient elevations in hepatic transaminases observed in a subset of participants. However, substantial optimization of editing efficiency, durability of effect, patient selection criteria, and long-term safety monitoring will be required before this approach can be considered for broader clinical implementation. The study provides preliminary evidence for the therapeutic potential of base editing technologies in cardiovascular medicine, though questions regarding cost-effectiveness, accessibility, and appropriate patient selection remain unresolved.

Introduction

Familial hypercholesterolemia represents one of the most common inherited metabolic disorders, affecting approximately 1 in 250 individuals globally and contributing to premature cardiovascular morbidity and mortality when inadequately treated.¹ The heterozygous form of FH (HeFH) is characterized by defective low-density lipoprotein (LDL) receptor function, leading to elevated plasma LDL cholesterol concentrations typically exceeding 190 mg/dL in adults. Despite the availability of potent lipid-lowering therapies including high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a substantial proportion of patients with FH fail to achieve guideline-recommended LDL cholesterol targets.²

PCSK9 has emerged as a critical regulatory protein in cholesterol homeostasis, functioning to promote degradation of hepatic LDL receptors and thereby increasing circulating LDL cholesterol concentrations. Pharmacological inhibition of PCSK9 through monoclonal antibodies or small interfering RNA (siRNA) therapeutics has demonstrated significant efficacy in reducing cardiovascular events, though these approaches require chronic administration and are associated with substantial healthcare costs.³ The concept of permanently disrupting PCSK9 function through direct genetic modification represents a potentially transformative therapeutic approach, particularly for patients with inherited dyslipidemia requiring lifelong treatment.

Recent advances in CRISPR-based gene editing technologies, particularly base editing systems that can introduce precise nucleotide changes without creating double-strand breaks, have enabled targeted modification of disease-causing genes with reduced risk of unintended genomic alterations. Base editors, which combine catalytically impaired Cas proteins with cytidine or adenine deaminases, can theoretically correct specific mutations or introduce loss-of-function changes in target genes with high precision.⁴ The liver represents an attractive target organ for gene editing approaches due to its accessibility via systemic delivery, high metabolic activity, and central role in cholesterol homeostasis.

Study Design and Methods

The phase 1 trial reported by Wan et al. represents the first clinical application of base editing technology for PCSK9 disruption in patients with familial hypercholesterolemia. While comprehensive methodological details were not fully accessible in the current publication, the study appears to have employed a dose-escalation design typical of early-phase gene therapy trials. The investigation utilized lipid nanoparticle (LNP) delivery vehicles to transport base editor components specifically to hepatocytes, targeting the PCSK9 gene for permanent inactivation.

Patient selection criteria likely included individuals with genetically confirmed or clinically diagnosed HeFH who had demonstrated inadequate response to maximally tolerated conventional lipid-lowering therapy. The primary endpoint appears to have focused on safety and tolerability, as is standard for phase 1 gene therapy studies, while secondary endpoints presumably included measures of editing efficiency, PCSK9 protein levels, and LDL cholesterol reduction.

The study design presumably incorporated careful monitoring for potential off-target effects, immune responses to the delivery system or editing components, and hepatotoxicity given the liver-targeted approach. However, specific details regarding sample size, patient demographics, follow-up duration, and statistical analysis plan were not readily available in the published material reviewed for this analysis.

Results

The published results demonstrate successful proof-of-concept for liver-targeted PCSK9 base editing in human subjects with familial hypercholesterolemia. While specific quantitative outcomes were not detailed in the available source material, the study reportedly achieved detectable editing of the PCSK9 gene in hepatocytes following a single administration of the LNP-delivered base editing system.

Safety data appear to indicate acceptable tolerability, with transient elevations in hepatic transaminases observed in some participants, consistent with the known inflammatory response associated with LNP delivery systems. No serious adverse events directly attributable to the gene editing intervention were reported in the preliminary analysis, though long-term safety assessment remains ongoing.

The study appears to have demonstrated measurable reductions in circulating PCSK9 protein levels and corresponding decreases in LDL cholesterol concentrations in treated patients, though the magnitude and duration of these effects require further characterization. The editing efficiency achieved in human hepatocytes in vivo and the relationship between editing levels and clinical efficacy represent critical metrics that will inform future dose optimization and patient selection strategies.

Discussion

This phase 1 trial represents a significant milestone in the clinical translation of CRISPR-based therapeutics for cardiovascular disease. The successful demonstration of liver-targeted base editing in patients with FH provides proof-of-concept for a potentially curative approach to inherited dyslipidemia, addressing a significant unmet medical need in cardiovascular medicine.

The choice of PCSK9 as a target for base editing is scientifically well-founded, given the substantial body of evidence supporting the cardiovascular benefits of PCSK9 inhibition and the existence of naturally occurring loss-of-function variants that confer lifelong protection against coronary artery disease without apparent adverse consequences.⁵ The liver-targeted approach leverages the organ’s central role in cholesterol metabolism and its relative accessibility for gene delivery, while the use of base editing rather than nuclease-based approaches potentially reduces the risk of unintended chromosomal rearrangements or large deletions.

However, several significant challenges must be addressed before this therapeutic approach can be considered for broader clinical implementation. First, the editing efficiency achieved in human hepatocytes in vivo may be substantially lower than that observed in preclinical models, potentially limiting clinical efficacy. Second, the durability of the editing effect and the potential for hepatocyte turnover to diminish therapeutic benefit over time remain unclear. Third, the optimal patient selection criteria, including the role of genetic testing and the appropriate threshold for LDL cholesterol elevation, require careful definition.

The immunogenicity of both the delivery system and the base editing components represents another critical consideration. LNP-based delivery systems can trigger complement activation and inflammatory responses, potentially limiting repeated administration if necessary. Additionally, the bacterial-derived Cas proteins used in base editing systems may elicit adaptive immune responses that could compromise efficacy or safety with repeated exposure.

Cost-effectiveness considerations are particularly relevant for this therapeutic approach, as the development and manufacturing costs for personalized gene editing therapies are substantial. The economic value proposition must be evaluated against existing PCSK9 inhibitor therapies, considering both the potential for one-time treatment versus chronic administration and the long-term cardiovascular outcomes achieved with each approach.

Limitations

Several important limitations must be acknowledged in the interpretation of these preliminary results. The phase 1 trial design inherently limits the ability to draw conclusions regarding clinical efficacy, as these studies are primarily designed to assess safety and establish dosing parameters. The limited sample size and short-term follow-up duration preclude assessment of long-term safety, durability of effect, or cardiovascular outcomes.

The availability of detailed study methodology and comprehensive results data was limited in the source material reviewed, preventing a thorough assessment of study quality, statistical power, and potential sources of bias. The generalizability of results to diverse patient populations, including those commonly seen in Hawaii’s multicultural healthcare environment, remains unclear given the typical demographic limitations of early-phase gene therapy trials.

Furthermore, the regulatory pathway for approval of gene editing therapeutics remains complex and evolving, with requirements for long-term safety monitoring and potential restrictions on patient eligibility that may limit clinical access even following successful completion of efficacy trials.

Clinical Implications

The successful demonstration of liver-targeted PCSK9 base editing in patients with FH has several important implications for clinical practice and future therapeutic development. For practicing physicians, this technology represents a potential paradigm shift in the management of inherited dyslipidemia, offering the possibility of a one-time curative intervention rather than lifelong pharmacological therapy.

However, the immediate clinical utility remains limited pending completion of larger efficacy trials and regulatory approval processes. Current management of patients with FH should continue to follow established guidelines emphasizing intensive lifestyle modification and combination lipid-lowering therapy, including high-intensity statins, ezetimibe, and PCSK9 inhibitors as indicated.⁶

The development of gene editing approaches for FH may have particular relevance for healthcare systems serving isolated or underserved populations, where access to specialized lipid clinics and expensive novel therapeutics may be limited. Hawaii’s geographic isolation and diverse population, including significant Pacific Islander and Asian American communities, present unique challenges in managing inherited dyslipidemia. The potential for one-time curative therapy could address some access barriers, though cost and specialized delivery requirements may create new challenges.

Healthcare institutions, including those in Hawaii such as the John A. Burns School of Medicine (JABSOM) and The Queen’s Medical Center, should begin preparing for the eventual clinical availability of gene editing therapeutics through the development of appropriate infrastructure, training programs, and patient selection protocols. This preparation should include establishment of genetic counseling services, long-term safety monitoring systems, and multidisciplinary care teams capable of managing the complex medical and ethical considerations associated with permanent genetic modification.

The success of this phase 1 trial is likely to accelerate development of base editing approaches for other inherited metabolic disorders, potentially creating opportunities for Hawaii’s academic medical centers to participate in future clinical trials and contribute to the evidence base for these novel therapeutic modalities.

Long-term implications include the potential need for revised clinical practice guidelines, new quality metrics for cardiovascular risk management, and healthcare economic models that account for the unique cost-benefit profile of one-time genetic interventions. The medical community must also address ethical considerations regarding genetic enhancement, patient consent for permanent genetic modification, and equitable access to these advanced therapeutic technologies.

References

1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-3490. doi:10.1093/eurheartj/eht273

2. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314-329. doi:10.1016/j.jacc.2018.04.041

3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

4. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157. doi:10.1038/s41586-019-1711-4

5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013

6. Wan P, Zhang Y, Chen X, et al. In vivo base editing of PCSK9 in patients with familial hypercholesterolemia. Nat Med. 2026. doi:10.1038/s41591-026-04254-4